Debiopharm Announces Phase III Positive Results for Triptorelin 6-month Formulation

News   May 22, 2015

 
Debiopharm Announces Phase III Positive Results for Triptorelin 6-month Formulation
 
 
 

RELATED ARTICLES

Safety and Efficacy of MERS Treatment Confirmed in Phase I Trial

News

An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.

READ MORE

Alzheimer’s Drug Discovery Foundation Announces $1.8M in New Funding

News

The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.

READ MORE

£70M Meant for Cancer Drug Development is Reassigned to Prepare for Brexit

News

At the end of last year, the Health Committee held a meeting to discuss Brexit, more specifically the impact this will have on the discovery, development and regulation of medicines, medical devices and biopharmaceuticals.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE